SCHEMBL6984460

SCHEMBL6984460

Nc1cccc2cc(C(=O)N3CCc4ccccc4C3)cnc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 9/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
HTT P42858 1/20 0.55
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 1/20 0.48
GAA P10253 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
CHRNB4 P30926 1/20 0.47
CHRNA3 P32297 1/20 0.47
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
LMNA P02545 1/20 0.46
LOX P28300 1/20 0.46
LOXL2 Q9Y4K0 1/20 0.46
NAMPT P43490 1/20 0.46
HSP90AA1 P07900 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6975645 0.74 HPGD (0.47) HPGDSMN1; SMN2HTTALDH1A1KDM4E
SCHEMBL12459664 0.72 CA1 (0.70) HPGDSMN1; SMN2HTTALDH1A1CA1
SCHEMBL3282222 0.72 MGAM (0.54) HPGDSMN1; SMN2HTTALDH1A1KDM4E
SCHEMBL31696721 0.72 PSMD14 (0.65) ALDH1A1KDM4ELMNA
SCHEMBL28171533 0.72 PSMD14 (0.65) ALDH1A1KDM4ELMNA
SCHEMBL6986553 0.72 PSMD14 (0.68) SMN1; SMN2
SCHEMBL4279383 0.71 HPGD (0.73) HPGDSMN1; SMN2HTTALDH1A1CA1
SCHEMBL30277860 0.71 HPGD (0.73) HPGDSMN1; SMN2HTTALDH1A1CA1
SCHEMBL30553441 0.70 PSMD14 (0.50) HPGDALDH1A1KDM4E
SCHEMBL27214185 0.70 PSMD14 (0.50) HPGDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 HPGD 802/4885SMN1; SMN2 3757/4885HTT 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.